Drug Trial Radar · NCT05732402
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
72
Actual
Start
Mar 15, 2023
Primary completion
Mar 2, 2028
Study completion Mar 2, 2028
Sponsor
- Lead sponsor
- Alpine Immune Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. Participants with IgAN and pMN may also receive povetacicept for an additional 52 weeks, if eligible.
Conditions
- Lupus Nephritis
- Immunoglobulin A Nephropathy
- Membranous Nephropathy
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
PovetaciceptDrug
Administered by subcutaneous injection every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Study Day 1 Through 24 Weeks After Last Dose Of Study Drug
- Part B: Safety as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Study Day 1 Through 12 Weeks After Last Dose Of Study Drug
Locations
30 sites in 4 countries. Site status is shown where the registry gives one.
Investigational Site (523)
Phoenix, Arizona
Investigational Site (501)
Phoenix, Arizona
Investigational Site (524)
Tucson, Arizona
Investigational Site (506)
Valencia, California
Investigational Site (513)
Arvada, Colorado
Investigational Site (512)
Orlando, Florida
Investigational Site (525)
Tamarac, Florida
Investigational Site (502)
Lawrenceville, Georgia
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Investigational Site (503)
Boston, Massachusetts
Washington University School of Medicine in St. Louis
St Louis, Missouri
Investigational Site (509)
Newark, New Jersey
Investigational Site (511)
Albany, New York
Investigational Site (508)
Brooklyn, New York
Investigational Site (518)
Bethlehem, Pennsylvania
Investigational Site (118)
Colleyville, Texas
Investigational Site (516)
Houston, Texas
Investigational Site (526)
Irving, Texas
Investigational Site (519)
Concord, New South Wales, Australia
Investigational Site (515)
Saint Albans, Victoria, Australia
Investigational Site (102)
Nedlands, Western Australia, Australia
Investigational Site (191)
Caguas, Puerto Rico
Investigational Site (507)
Cheonan, Chungcheongnam-do, South Korea
Investigational Site (505)
Anyang-si, Gyeonggi-do, South Korea
Investigational Site (504)
Goyang-si, Gyeonggi-do, South Korea
Investigational Site (510)
Guri-si, Gyeonggi-do, South Korea
Investigational Site (125)
Seoul, Gyeonggi-do, South Korea
Investigational Site (520)
Seoul, Gyeonggi-do, South Korea
Investigational Site (521)
Seoul, Gyeonggi-do, South Korea
Investigational Site (116)
Suwon, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.